/
ALT
$2.94+$0.12 (+4.26%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$548.4M
194M shares
52-week range
$2.56 – $6.44
10% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.26%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-6.91
Altimmune, Inc. Common Stock
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
www.altimmune.com- Employees
- 57
- IPO / List date
- Oct 6, 2005
- HQ
- GAITHERSBURG, MD
Held by traders on TradeandTell
No one on the platform currently holds ALT.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in ALT as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2018-09-14 | 1-for-30reverse |
| 2017-05-04 | 1-for-10reverse |
| 2007-07-25 | 1-for-50reverse |
Recent trades on TradeandTell
No one on the platform has traded ALT yet.
